Interviews

Dr Elisabet Manasanch Highlights MRD Assessment Accuracy in Predicting Treatment Progression
April 07, 2020 – 
MRD assessments are probably 1 of the most powerful predictors that we have to see how well a treatment has worked, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr Elisabet Manasanch Speaks on Checking for MRD After Treatment for Multiple Myeloma
April 03, 2020 – 
Following the International Myeloma Working Group criteria, we usually check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr Michael Diaz Explains Challenges to Capturing Electronic Patient-Reported Outcomes
March 30, 2020 – 
Part of the reason COA recommended a 'ramp up' period is we need time for the vendors to understand what they need to be incorporating in their software, said Michael Diaz, MD, president of Community Oncology Alliance.
Dr Lucio Gordan Outlines Challenges to Implementing a New OCM
March 27, 2020 – 
"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.
Dr Elisabet Manasanch: As Data Build on Effectiveness of MRD Testing, Adherence Will Increase
March 24, 2020 – 
Although it is true that there are people who still don't use minimal residual disease (MRD) testing, I think that its use is going to pick up based on results of emerging clinical studies, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr Maen Hussein on How Changes in Medicare Hospice Coverage Impact Community Oncology Practices
March 21, 2020 – 
"There is this mentality that hospice means the patient is going to die very soon, and that's really not true," said Maen Hussein, MD, physician director of finance at Florida Cancer Specialists.
Dr Elisabet Manasanch Outlines Potential of MRD Testing for Treatment Decision Making
March 20, 2020 – 
Right now, it's not really used for decision treatment in most centers, but there are a lot of studies that have started this year or starting next year that have MRD as an endpoint so we will see, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Dr Jeffrey Lowenkron Outlines Barriers to Care Coordination Among Medicare Beneficiaries
March 19, 2020 – 
Sharing records and encouraging conversation will promote better collaboration between primary care and cancer care, said Jeffrey Lowenkron, MD, chief medical officer of The Villages Health.
Dr Michael Diaz on How a Delay to an OCM Successor Will Benefit Practices
March 19, 2020 – 
"We want to make sure practices have time to learn, understand, adapt, and modify, to a new Oncology Care Model," said Michael Diaz, MD, president of Community Oncology Alliance.
Dr Karl Kilgore Outlines Challenges of Collecting Real-World Data on CAR T-Cell Therapy
March 18, 2020 – 
Several challenges arise when using real-world data derived from claims to study the impacts of CAR T-cell therapy on Medicare patients, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.